Skip to content

GenePOC™ Carba 133499

by Genepoc, Inc.

GenePOC Carba 133499, a multiple antimicrobial resistance nucleic acid IVD (FDA Class II) made by Genepoc, Inc., was listed in FDA GUDID on 24 May 2019 (UDI-DI 00628055344070); the registry lists it as not in commercial distribution (GUDID) as of 23 Oct 2026.

Listed FDA GUDID listing, not in commercial distribution

Valid until

Not applicable

Database listing, no authorization

FDA recalls

Not checked

No FDA submission to match recalls against

Documents

None

No authorization documents

Trust

Unverified

Source GUDID, synced 23 Oct 2026.

Regulatory status

as of registry sync 23 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesGUDID listing Number00628055344070 UDI-DI Date24 May 2019ListedStatusListed GUDID: not in commercial distribution

Official records

From the FDA record

Device description
The GenePOC™ Carba assay, performed on the revogene™ instrument, is a qualitative in vitro diagnostic test designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences associated with carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa, when grown on blood agar or MacConkey agar. The test utilizes automated real-time Polymerase Chain Reaction (PCR). The GenePOC Carba assay should be used in conjunction with other laboratory tests including phenotypic antimicrobial susceptibility testing. A negative GenePOC Carba assay result does not preclude the presence of other resistance mechanisms. The GenePOC Carba assay is intended as an aid for infection control in the detection of carbapenem-non-susceptible bacteria that colonize patients in healthcare settings. The identification of a blaIMP, blaNDM or blaVIM metallo-B-lactamase gene (i.e., the genes that encode the IMP, NDM and VIM metallo-B-lactamases, respectively) may be used as an aid to clinicians in determining appropriate therapeutic strategies for patients with known or suspected carbapenem non-susceptible infections.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 23 Oct 2026, as the labeller entered it.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — GUDID listing Listed

Specification

GUDID

Trade name
GenePOC™ Carba
Generic name
Multiple antimicrobial resistance nucleic acid IVD, kit, nucleic acid technique (NAT)
Model / Ref / Catalog
133499
Primary DI / UDI-DI
00628055344070
FDA product code
OOI, PMY
GMDN term
Multiple antimicrobial resistance nucleic acid IVD, kit, nucleic acid technique (NAT)
Device class
Class II
Regulation number
862.2570, 866.1640
GUDID distribution status
Not in Commercial Distribution

Similar devices

Other devices filed under FDA product code OOI (Real Time Nucleic Acid Amplification System).

Other devices from Genepoc, Inc.

  • revogene™ 130840 Open recall

    Class II
  • GenePOC CDiff Open recall

    Class II
  • GenePOC Carba

    Class II
  • revogene Open recall

    Class II

See all devices from Genepoc, Inc. →

Properties

  • Single use
  • Prescription use
  • Convenience kit
  • Lot / batch number
  • Expiration date
Other properties (10, all answered No)